Skip to main content

Table 1 gBRCAm prevalence by region of enrollment (FAS)

From: Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

 

Asia (N = 104)

Europe (N = 199)

North America (N = 33)

Australia/Oceania (N = 5)

FAS (N = 341)

Positive for a gBRCAm, n (% [95% CI])

11 (10.6 [5.4, 18.1])

18 (9.0 [5.4, 13.9])

3 (9.1 [1.9, 24.3])

1 (20.0 [0.5, 71.6])

33 (9.7 [6.8, 13.3])

gBRCA1m only, n (% [95% CI])

6 (5.8 [2.1, 12.1])

10 (5.0 [2.4, 9.0])

0 (0.0 [0.0, 10.6])

0 (0.0 [0.0, 52.2])

16 (4.7 [2.7, 7.5])

gBRCA2m only, n (% [95% CI])

5 (4.8 [1.6, 10.9])

6 (3.0 [1.1, 6.4])

1 (3.0 [0.1, 15.8])

0 (0.0 [0.0, 52.2])

12 (3.5 [1.8, 6.1])

Both gBRCA1m and gBRCA2m, n (% [95% CI])

0 (0.0 [0.0, 3.5])

2 (1.0 [0.1, 3.6])

2 (6.1 [0.7, 20.2])

1 (20.0 [0.5, 71.6])

5 (1.5 [0.5, 3.4])

  1. BRCA breast cancer susceptibility gene, CI confidence interval, FAS full analysis set, gBRCAm germline BRCA mutation
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us